Metered Cryospray treats damaged airways enabling a rejuvenative healing response BOSTON, Sept. 6, 2022 /PRNewswire/ — CSA Medical, Inc., today announced results from the first randomized, controlled study of Metered Cryospray (MCS) utilizing the...
These results should provide the scientific proof behind the remodeling response and clinical improvements identified in earlier studies Boston, MA—May 12, 2021: CSA Medical, Inc., today announced ® that all subjects have been enrolled in the RejuvenAir System study...
Boston, MA –April 19, 2021: CSA Medical, Inc., today announced that Wissam Abouzgheib, MD, chief of pulmonary medicine at Cooper University Health Care, Camden, New Jersey, has joined the SPRAY-CB Study investigating a new device treatment for COPD with Chronic...
The RejuvenAir System is designed to address the underlying cause of COPD with Chronic Bronchitis and enable rejuvenative healing of the airways BOSTON, Nov. 23, 2020 — CSA Medical, Inc., today announced metered cryospray utilizing the RejuvenAir® System for the...
This study will provide a scientific rationale for the remodeling response and clinical improvements identified in the feasibility study Boston, MA –November 11, 2020: CSA Medical, Inc., today announced that over half of the subjects in a 32 patient study,...
Published by Mass Device Medical Network CSA Medical announced this week that it won CE Mark approval for its RejuvenAir system for treating chronic obstructive pulmonary disease (COPD) with chronic bronchitis (CB). The RejuvenAir system that is designed to apply...
CAUTION: When reading this news item please be aware that the RejuvenAir System is an Investigational device, limited by United States Federal law to investigational use only. Not for Sale in the United States of America.